07:00 , May 10, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Cancer BT Alex. Brown analyst Dennis Harp said the remarkably strong Phase II data on AMGN's abarelix compound in prostate cancer bode well for the compound, which has...
07:00 , May 10, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Pharmacopeia Inc. (PCOP), Princeton, N.J. Business: Drug discovery BT Alex. Brown analyst Kevin Tang raised his rating to "strong buy" from "buy" based on expected 20 percent revenue growth this year driven by new combinatorial...
07:00 , May 10, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

QLT PhotoTherapeutics Inc. (QLTI), Vancouver, B.C. Business: Cancer BT Alex. Brown analyst Kevin Tang began coverage with a "strong buy" and a $62 price target, saying the company is one of a handful positioned to...
08:00 , Mar 22, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Metabolic BT Alex. Brown analyst Dennis Harp raised his price target to $43 from $39 after TKTX licensed rights to iduronate 2-sulfatase, an enzyme missing or deficient in...
08:00 , Mar 15, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN) , Thousand Oaks, Calif. Business: Biopharmaceuticals BT Alex. Brown analyst Dennis Harp raised his price target to $80 from $68. The licensing of Praecis Pharmaceuticals Inc. 's abarelix for prostate cancer gives...
08:00 , Mar 8, 1999 |  BioCentury  |  Finance

Choppy waters

Small waves of optimism and pessimism are roiling the waters as another life science company stepped up to sell an IPO, while two NASDAQ IPOs have been put on ice, including cancer vaccine play Intracel...
08:00 , Feb 16, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Pharmacopeia Inc. (PCOP), Princeton, N.J. Business: Drug discovery BT Alex. Brown analyst Kevin Tang raised his 1999 EPS estimate to $0.00 from ($0.06) to reflect better than expected fourth quarter results and management guidance. He...
08:00 , Feb 1, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals PaineWebber analyst Elise Wang raised her price target to $150 from $137 after AMGN beat her 1998 EPS estimate of $3.22 by $0.05. She raised her Epogen...
08:00 , Jan 25, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Pharmacopeia Inc. (PCOP), Princeton, N.J. Business: Drug discovery BT Alex. Brown analyst Kevin Tang raised his 1999 EPS estimate to ($0.06) from ($0.11) and his 2000 EPS estimate to $0.23 from $0.17 following the company's...
08:00 , Jan 11, 1999 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Immunex Corp. (IMNX), Seattle, Wash. Business: Autoimmune/Inflammation BancBoston Robertson Stephens analyst Michael King began coverage of IMNX with a "long-term attractive" rating and a $130 price target. He expects Enbrel for rheumatoid arthritis will rank...